NCT00770120 · OUTCOME

Overall Survival

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery · Source last updated 2020-03-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Every 8 weeks until disease progression, up to 3 years.

What was measured

Overall survival was defined as the duration between the date of enrollment and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.

Groups in this outcome

Everolimus

Daily oral Everolimus 10 mg/day everolimus

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Everolimus	59

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Everolimus	6.3	Not reported	4.8	8	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
4.8
upper Limit
8
value
6.3

denoms

counts
group Id
OG000
value
59
units
Participants

description

Overall survival was defined as the duration between the date of enrollment and the date of death due to any cause. Patients last known to be alive were censored at the date of last contact.

dispersion Type

95% Confidence Interval

groups

description
Daily oral Everolimus 10 mg/day everolimus
id
OG000
title
Everolimus

param Type

MEDIAN

reporting Status

POSTED

time Frame

Every 8 weeks until disease progression, up to 3 years.

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice